Antibiotic resistance is an urgent and growing global problem. The pharmaceuticals industry has more or less stopped developing new types of antibiotics, which means that progress in this field largely depends on research at universities and small biotech companies. The situation demands new solutions and partnerships.
Uppsala University is home to national and international interdisciplinary expertise in the field of antibiotic resistance. In addition to strong basic research in medicinal products, microbiology and antibiotic resistance, there is internationally outstanding research in diagnostics, new economic models, law, clinical research, ethics, global health, sustainable development, behaviour and learning.
Research in antibiotics
Rapid testing for antibiotic resistance
17 November 2020. In cases of severe infection, identifying the correct antibiotic – and doing so quickly – can be a m ...
Successful antibiotic cooperation being led from Uppsala University
9 November 2020. The COVID-19 pandemic has not halted work to identify needs and uses for antibiotics. The PLATINEA c ...
Study of patient meetings will contribute to sustainable antibiotic-prescribing practices
27 January 2020. By studying social and linguistic patterns in doctor-patient meetings, Anna Lindström, professor of ...
Research projects and networks in antibiotics
Uppsala University also leads several major research projects and networks in the field of antibiotics, some of which are international and have EU support.
Uppsala Antibiotic Center – UAC
A centre for research, education and innovation aimed at tackling and finding solutions to the global challenge of antibiotic resistance. UAC conducts interdisciplinary research and education on antibiotic resistance involving all three disciplinary domains at Uppsala University. The centre was inaugurated in autumn 2016 and 14 interdisciplinary doctoral projects have been in progress here since 2017.
European Gram Negative AntiBacterial Engine – ENABLE
The ENABLE project was launched in February 2014, within the framework of the Innovative Medicines Initiatives (IMI) programme “New Drugs for Bad Bugs” (ND4BB), with Uppsala University and pharmaceuticals company GlaxoSmithKline as the key actors. The goal of the six-year project is to develop antimicrobial drug candidates for clinical trials so as to increase the chances of finding new antibiotics against infections caused by Gram-negative bacteria. The consortium consists of 39 different partners from all over Europe, from academia, research institutes, small and medium-sized biotech companies and major pharmaceutical concerns.
Collaboration for Prevention and Treatment of MDR Bacterial Infections – COMBINE
A multinational collaboration, in which Uppsala University has a leading role. Eleven partners from academia and industry in seven European countries are together seeking to pave the way for more effective antibiotic development. The project runs from 1 November 2019 until 31 October 2025. It is backed by the Innovative Medicines Initiative (IMI) – a partnership between the EU and the EFPIA (European Federation of Pharmaceutical Industries and Associations).
Platform for Innovation of Existing Antibiotics – PLATINEA
A collaboration platform that aims to improve access to and optimise the use of antibiotics. The platform is funded by VINNOVA and consists of 15 actors from academia, public authorities, industry and health services. The objective is to ensure that existing antibiotics are used in the best possible way and to guarantee access to important antibiotics that risk disappearing from Sweden. The platform involves continuous identification and prioritisation of antibiotic needs, as well as new studies for the adaptation of antibiotics dosage. The project will also evaluate and test new tools to promote rational antibiotics use and investigate existing supply chains for antibiotics.
Action on Antibiotic Resistance – ReAct
ReAct is an Uppsala-based international network that has played an important international role in recent years in the approach to developing new antibiotics. The network applies a health system perspective to antibiotic resistance. It seeks to promote a new business model that encourages the public and private sectors to cooperate in tackling the scientific challenges, while creating innovative financial and other incentives. Uppsala therefore excels not only in research on antibiotic resistance but also in the dissemination of information and advocacy.